8 employees
CanSense is an accurate, rapid, non-invasive, blood diagnostic for the early detection of cancer.
2018
$1.8M
from 3 investors over 3 rounds
CanSense raised $1.8M on March 8, 2023
Investors: - and Development Bank of Wales
CanSense raised $1.4M on January 1, 2022
Investors: National Institute for Health Research (NIHR)